Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

In brief

The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.

Key facts

Study ID

NCT04501120

Run by

Ascentage Pharma Group Inc.

People needed

682

Starts

2020-09-28

Expected to finish

2029-09-01

Last updated by the study team

2026-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects who meet each of the following inclusion criteria are eligible to participate in this study:
• In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for relapsed or refractory acute myeloid leukemia (AML), Mixed phenotype acute leukemia(MPAL), Chronic myelomonocytic leukemia (CMML), Higher-risk myelodysplastic syndrome (HR-MDS) , Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and naïve AML ineligible for treatment with a standard chemotherapy due to age or comorbidities.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2 (0 to 3 for participants >= 60 to 74 years of age who are evaluated as ineligible for treatment with standard chemotherapy).
• Subjects can accept oral administration of Lisaftoclax (APG-2575).
• Life expectancy ≥ 3 months.
• Adequate renal and liver function.
• Males, female patients of childbearing potential (postmenopausal women who must have been menopausal for at least 12 months to be considered infertile) and their partners voluntarily take contraception which the investigator considers effective during treatment and at least three months after the last dose of study drug.
• Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).
• Willingness and ability to comply with study procedures and follow-up examination.

You may not qualify if…

• Patients who meet any of the following exclusion criteria are not to be enrolled in this study:
• Patients diagnosed with acute promyelocytic leukemia or t(9;22)(q34.1;q11.2); BCR-ABL1 positive AML patients.
• The persistent toxicities caused by previous chemotherapy or radiotherapy has not been restored to lower than grade 2 by CTCAE 5.0 (except for alopecia).
• Known leukemia infiltration of the central nervous system.
• Symptomatic active fungal, bacterial and/or viral infections.
• Prior history of allogeneic hematopoietic stem cell transplantation or adoptive cell immunotherapy, autologous hematopoietic stem cell transplantation within 12 months.
• Within 14 days before the first dose of study drug, received chemotherapy (hydroxyurea is permitted more than 24 hours before the first dose of study drug), radiotherapy, surgery, immunotherapy, targeted therapy, biological therapy or any investigational treatment.
• Within 7 days before the first dose of study drug, received a strong and/or moderate CYP3A inducer and/or Inhibitor.
• At the discretion of the investigator, gastrointestinal diseases that affect the absorption of Lisaftoclax (APG-2575).
• Any other condition or circumstance, at the discretion of the investigator, that patients would be unsuitable for participation in the study.

Where it is running

• the First Affiliated Hospital, College of Medicine, Zhejiang University — Hangzhou, Zhejiang, China (enrolling)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)
• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)
• Sun Yat-sen University Cancer Center — Guangzhou, Guandong, China (enrolling)
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
• Henan Tumor Hospital — Zhengzhou, Henan, China (enrolling)
• Union Hospital medical college Huazhong University of Science and Technology — Wuhan, Hubei, China (enrolling)
• Zhongnan Hospital of Hunan university — Wuhan, Hubei, China (enrolling)
• Xiangya Hospital Central South University — Changsha, Hunan, China (enrolling)
• The First affiliated hospital of Soochow University — Suzhou, Jiangsu, China (enrolling)
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China
• Shanghai The Sixth People' s Hospital — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.